Ann: Appendix 4C, page-8

ColoSTAT has three distinct advantages over COLVERA:

1. Significant cost savings;
2. Fits perfectly into existing lab based ELISA type technology, without the need for new equipment; and
3. Greater sensitivity and accuracy.

Source: http://sprout8.com/rhy-research-report/ Relevant sections of the report pasted below:

Efficacy

"Comparing performance of ColoSTAT™ to FIT and Colvera, the leading molecular candidate, Colvera on the same patients showed sensitivities of

1. Colvera: All stage cancer, 62%; Stage1, 41.2%; Stage II, 76%; Stage III, 59% and StageIV 71.4%, all at 91.8% specificity
2. ColoSTAT™: All stage cancer, 73%; Stage 1, 58%; Stage II, 80%; Stage III, 73.5% and Stage IV, 83%, all at 95% specificity."

Convenience


"1. Only a small volume of serum is required for ColoSTAT (less than 0.1 mL) meaning the test can be easily added to a panel of standard blood tests being ordered by a physician as part of a patient’s annual check-up without the need for its own specific blood draw. By comparison, around 4 mL of blood plasma is required to run Colvera tests where DNA is extracted from blood plasma, meaning it is not easily run currently as an adjunct to another panel of tests performed on the same blood draw.

2. Furthermore ColoSTAT technology fits perfectly into existing lab based ELISA type technology without the need to purchase new equipment or hire specialist staff, will give a competitive cost advantage."

Cost

"ColoSTAT™ is based on protein which means it is a low cost of manufacture and utilises ELISA assays using specific antibody binding sites to detect a protein, which are common in diagnostic labs without the need to purchase additional equipment."

Cheers,

5x8's